Table 2.
Distributions of patients’ characteristics among complete cases and multiple imputation.
| Complete case (N = 288) | Multiple imputation (N = 369) | |
|---|---|---|
| Female | 150 (52.1%) | 188 (50.9%) |
| Age (years) | 49.0 (42.0–56.0) | 49.0 (42.0–56.0) |
| Age ≥ 50 years | 138 (47.9%) | 181 (49.1%) |
| Liver cirrhosis | 23 (8.0%) | 36 (9.8%) |
| HCV RNA(lg10 IU/L) | 6.0 (5.2–6.4) | 5.9 (5.2–6.5) |
| HCV Genotype | ||
| 1 | 120 (41.7%) | 154 (41.7%) |
| 2 | 21 (7.3%) | 28 (7.6%) |
| 3 | 112 (38.9%) | 138 (37.4%) |
| 6 | 26 (9.0%) | 37 (10.0%) |
| Unknown | 9 (3.1%) | 12 (3.3%) |
| Total bilirubin (μmol/L) | 12.5 (9.5–16.8) | 12.6 (9.4–17.2) |
| Alanine aminotransferase (×ULN) | 1.4 (0.9–2.4) | 1.4 (0.9–2.5) |
| Alanine aminotransferase >2 × ULN | 100 (34.7%) | 130 (35.2%) |
| Albumin (g/L) | 44.3 (41.1–47.0) | 44.2 (40.8–46.8) |
| Serum creatinine (×ULN) | 0.6 (0.5–0.7) | 0.6 (0.5–0.7) |
| Platelet (×109/L) | 144.0 (103.0–189.5) | 144.0 (100.5–189.0) |
| Platelet >100 × 109/L | 223 (77.4%) | 277 (75.1%) |
| SII | 238.2 (153.0–358.2) | 228.3 (146.6–345.8) |
| Ribavirin administration | 108 (37.5%) | 135 (36.6%) |
| SVR12 | 287 (99.7%) | 366 (99.2%) |
| Outcome of liver fibrosis | ||
| Non-improved APRI | 239 (83.0%) | 299 (81.0%) |
| Non-improved FIB-4 | 252 (87.5%) | 323 (87.5%) |
SII, systemic immune-inflammation index; HCV, hepatitis C virus; ULN, upper limit of normal; SVR12, HCV RNA less than 15 IU/mL 12 weeks after cessation of antiviral therapy; FIB-4, fibrosis-4; APRI, aspartate aminotransferase-to-platelet ratio index. Quantitative data are presented as median (interquartile range). Qualitative data are presented as frequencies (proportions).